If you have spent any time on Indian Instagram, doctor reels, or weekend WhatsApp groups in the last twelve months, you have heard the names. Ozempic. Mounjaro.
Two once-a-week injections that have completely changed how diabetes and obesity are treated, and that now sit inside Indian pharmacies under regulator-approved labels.
But here is where most articles get lazy: they treat the two drugs as interchangeable. They are not. They have different molecules, different mechanisms, different efficacy in head-to-head trials, and very different availability stories in India right now.
This guide walks through what actually matters before you ask your endocrinologist for a prescription.
| Key takeawaysDifferent molecules: Ozempic is semaglutide (single GLP-1 agonist). Mounjaro is tirzepatide (dual GLP-1 and GIP agonist).Head-to-head efficacy: In the SURMOUNT-5 trial, Mounjaro produced 20.2% mean weight loss at 72 weeks vs 13.7% on semaglutide. For diabetes, SURPASS-2 showed superior HbA1c control on Mounjaro across all doses.India launch timeline: Mounjaro launched March 2025 and became India’s top-selling drug by value by October 2025. Ozempic launched 12 December 2025.Do not combine: Taking Mounjaro and Ozempic together is not safe. Both hit the GLP-1 pathway; stacking doubles the side effect risk without doubling the benefit. |
So what exactly are Ozempic and Mounjaro?
Both belong to a class of drugs called GLP-1 receptor agonists.
They mimic gut hormones that the body naturally releases after a meal, which signal the pancreas to release insulin, slow down stomach emptying, and tell the brain that you are full. The result is better blood sugar control and, almost as a side effect, significant weight loss.
Where they differ is in the molecule itself.
Ozempic uses semaglutide
Made by Novo Nordisk, Ozempic is the brand name for semaglutide, a single-target drug that mimics only one hormone: GLP-1.
It was approved by the US FDA in 2017 for type 2 diabetes and is used off-label in many markets for weight loss. The same molecule, at a higher dose, is sold as Wegovy specifically for weight management.
Mounjaro uses tirzepatide
Made by Eli Lilly, Mounjaro is the brand name for tirzepatide, a dual-target drug. It mimics two hormones, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).
That second receptor is the reason most clinicians describe Mounjaro as a generational step up from semaglutide. In the US, the same molecule is also sold as Zepbound for obesity.
Here is the snapshot:
| Feature | Ozempic | Mounjaro |
|---|---|---|
| Generic name | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Receptor target | GLP-1 only (single agonist) | GLP-1 and GIP (dual agonist) |
| Indian launch | December 2025 | March 2025 |
| Dose frequency | Once weekly injection | Once weekly injection |
| Indian-approved use | Type 2 diabetes | Type 2 diabetes and chronic weight management |
| Weight-loss sibling brand | Wegovy (semaglutide, higher dose) | Zepbound (tirzepatide, same molecule, branded for obesity abroad) |
Which one can you actually get in an Indian pharmacy right now?
This is the most overlooked part of the conversation, and it has changed dramatically in the last twelve months.
Mounjaro: launched first, scaled fast
Eli Lilly launched Mounjaro in India in March 2025, initially as single-dose vials in 2.5 mg and 5 mg strengths. By August 2025, the company introduced the easier-to-use KwikPen, a multi-dose prefilled pen designed for self-administration. According to Reuters reporting via Pharmarack, Mounjaro became India’s top-selling drug by value in October 2025, just seven months after launch, hitting INR 1 billion in monthly sales.
In October 2025, Eli Lilly also partnered with Cipla to distribute tirzepatide under a second brand name, Yurpeak, which expanded reach into chemist networks that Lilly does not service directly.
Ozempic: arrived late, but landed
Novo Nordisk took a different route in India. The company first launched Wegovy (the obesity-indication semaglutide) in June 2025.
Novo Nordisk also signed a co-marketing deal with Abbott India to distribute Ozempic under the brand name Extensior.
The semaglutide generics shift
Semaglutide’s Indian patent expired on 20 March 2026.
Within weeks, more than ten Indian pharma companies, including Dr. Reddy’s, Zydus, Sun Pharma, Cipla and Lupin, launched generic semaglutide brands at substantially lower price points.
As of early 2026, Novo Nordisk has cut Ozempic and Wegovy prices in India by up to 48% to defend market share against generics, per Invezz / Reuters reporting.
Tirzepatide is still on-patent in India. There are no Mounjaro generics yet. That single fact is reshaping the access conversation in ways your endocrinologist will already be factoring into prescriptions.
Which one works better, honestly?
This is where the marketing fog clears and the clinical data does the talking. Two head-to-head randomized trials have directly compared the two molecules.
Both were published in The New England Journal of Medicine, which is as high a bar as medical evidence gets.
For type 2 diabetes: the SURPASS-2 trial
In the SURPASS-2 trial, 1,879 adults with type 2 diabetes already on metformin were randomized to receive either tirzepatide or semaglutide (1 mg, the maximum diabetes dose at the time) for 40 weeks.
Results, published in Frías et al., NEJM 2021, showed all three tirzepatide doses delivered superior HbA1c reductions and superior body weight reductions compared to semaglutide.
The headline number: 60% of patients on tirzepatide 15 mg hit the combined target of HbA1c at or below 6.5% with at least 10% weight loss, without clinically significant hypoglycemia.
Only 22% of patients on semaglutide 1 mg achieved the same combined outcome.
For weight loss: the SURMOUNT-5 trial
The SURMOUNT-5 trial, published in Aronne et al., NEJM 2025, was the first direct head-to-head comparison for obesity.
It enrolled 751 adults with obesity or overweight plus at least one weight-related comorbidity, but without diabetes, and ran for 72 weeks.
| Outcome at 72 weeks | Tirzepatide (Mounjaro molecule) | Semaglutide (Ozempic molecule) |
|---|---|---|
| Mean body weight reduction | 20.2% | 13.7% |
| Mean absolute weight loss | 22.8 kg | 15.0 kg |
| Patients losing at least 25% body weight | 31.6% | 16.1% |
| GI side effects causing discontinuation | 2.7% | 5.6% |
The results were not close.That is a 47% greater relative weight reduction on tirzepatide, with fewer patients dropping out due to side effects.
SURMOUNT-5 was funded by Eli Lilly (worth flagging as a disclosure), but it was peer-reviewed by NEJM and run under standard phase 3 protocols.
So is Mounjaro better than Ozempic?
On raw efficacy for both diabetes and weight loss, yes, the trial data says Mounjaro outperforms Ozempic.
But raw efficacy is not the only thing that matters. Individual response varies. Some patients tolerate semaglutide better.
Some clinical situations (like advanced diabetic kidney disease, where semaglutide has the stronger published outcome trial via SELECT) make semaglutide the preferred choice.
And, as covered below, side effect profiles differ in ways that are worth talking through with your doctor.
What about side effects?
Both drugs share the same family-level side effect profile, because both work on the gut and brain pathways that regulate appetite.
The Indian Ministry of Health and Family Welfare advisory of April 2026 formally flagged the following risks for the entire GLP-1 class:
- Gastrointestinal effects (nausea, vomiting, diarrhea, constipation), most intense during dose escalation
- Acute pancreatitis
- Acute kidney injury, especially in patients dehydrated from GI symptoms
- Bowel obstruction and gastroparesis
- Gallstones and bile duct complications, linked to rapid weight loss
- Worsening of pre-existing diabetic retinopathy in some patients
- Possible thyroid C-cell tumour risk (seen in rodent studies, contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN-2)
Where the two drugs separate is in the GI side effect intensity. A real-world FDA adverse event analysis published in PMC found that semaglutide had a higher reporting rate of nausea, vomiting, diarrhea and constipation than other GLP-1s in its class.
In SURMOUNT-5, semaglutide patients discontinued treatment due to GI side effects at roughly twice the rate of tirzepatide patients (5.6% vs 2.7%).
Who should not take either of these drugs?
- Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- Anyone with a history of acute or chronic pancreatitis
- Anyone with severe gastroparesis
- Anyone who is pregnant or planning pregnancy within 2 months
- Anyone with a known allergy to semaglutide, tirzepatide or formulation excipients
None of this is meant as a scare tactic. These are real, documented risks that informed prescribers screen for before writing the first prescription.
Self-medicating either drug through grey-market channels is the single fastest way to turn a manageable risk into a hospital admission.
Can you just walk in and buy these in India?
No. And the rules tightened significantly in 2026.
Per the April 2026 advisory from the Indian Ministry of Health and Family Welfare, GLP-1 drugs in India can only be prescribed by:
- Endocrinologists
- Internal medicine specialists
- Cardiologists
General practitioners, gynaecologists, dermatologists and cosmetic clinics are not authorised to write the prescription.
Both Ozempic and Mounjaro are strictly Schedule H prescription medicines, and over-the-counter sale is illegal.
Indian regulators have also pushed back against pharma marketing that creates demand pressure on doctors. Eli Lilly’s “We Know Now” obesity awareness campaign was halted in April 2026 after CDSCO flagged it as an indirect promotion of Mounjaro, even though the brand name was never used.
Can you take Mounjaro and Ozempic together?
Short answer: No, and any responsible Indian endocrinologist will refuse to prescribe both.
Both drugs activate the same GLP-1 receptor pathway. Stacking them does not double the benefit; it stacks the side effect risk.
Severe nausea, dehydration, acute pancreatitis, gallstone attacks and hypoglycemia all become more likely.
US payers like MassHealth explicitly block reimbursement when GLP-1 agents are prescribed in combination, and Indian clinical practice follows the same logic: pick one, optimise the dose, escalate slowly.
If one drug is not working, the answer is to switch, not stack. A switch typically involves a washout period and a fresh dose-escalation schedule on the new molecule.
Wait, is Mounjaro the same as Wegovy? Or semaglutide?
This trips up a lot of people, so it is worth nailing down.
| Brand | Molecule | Indication |
|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes |
| Wegovy | Semaglutide (higher max dose, 2.4 mg) | Chronic weight management |
| Mounjaro | Tirzepatide | Type 2 diabetes and chronic weight management |
| Zepbound | Tirzepatide (same molecule as Mounjaro) | Chronic weight management (sold as Zepbound in some markets) |
So: Mounjaro is not Wegovy. Mounjaro is tirzepatide; Wegovy is semaglutide. And Mounjaro is not semaglutide either.
Mounjaro is tirzepatide, a different molecule that hits an extra receptor (GIP) on top of GLP-1.
So which one should you ask your doctor about?
Treat this as a conversation prompt with your specialist, not a self-prescription checklist. But here is the framework most Indian endocrinologists are using in 2026:
Choose Mounjaro (tirzepatide) if:
- Your primary goal is weight loss and you need significant reduction (15% or more of body weight)
- You have type 2 diabetes and weight loss is a co-priority
- You have struggled with semaglutide-related GI side effects in the past
- Your doctor wants the steepest efficacy curve and cost is manageable
Choose Ozempic (semaglutide) if:
- Your primary indication is type 2 diabetes (this is the only label-approved use of Ozempic in India)
- You have advanced diabetic kidney disease, where semaglutide has the stronger outcome trial evidence (the SELECT trial)
- Your doctor recommends a slower, more cautious dose escalation
- Generic semaglutide options are now widening access following the March 2026 patent expiry
Choose neither if:
- You do not have a clinical indication. These drugs are not lifestyle accessories.
- You cannot commit to staying on the drug long-term or transitioning to lifestyle maintenance. Most weight regain happens after stopping.
- You have any of the contraindications listed earlier in this guide.
Frequently asked questions
Is Mounjaro or Ozempic more effective for weight loss in India?
Based on the only head-to-head trial that has compared them directly (SURMOUNT-5), tirzepatide (Mounjaro) produced 20.2% mean body weight reduction at 72 weeks, compared to 13.7% on semaglutide (Ozempic-family molecule).
For most patients without diabetes-specific contraindications, Mounjaro is the more effective option for weight loss.
Which is available and prescribed more in India: Ozempic or Mounjaro?
Mounjaro. It launched nine months earlier than Ozempic (March 2025 vs December 2025), and by October 2025 it was India’s top-selling drug by value.
Pharmarack data referenced by Reuters showed 262,000 doses of Mounjaro sold in October 2025, compared with 26,000 doses of Wegovy.
Ozempic only joined the market in mid-December 2025, but is scaling fast through the Novo Nordisk and Abbott India co-marketing deal.
Is Ozempic available in Indian pharmacies right now?
Yes. Ozempic launched in India on 12 December 2025 and is stocked in major chain pharmacies and hospital outpatient pharmacies, available only against a prescription from an endocrinologist, internal medicine specialist or cardiologist.
Can I use Mounjaro for weight loss if I do not have diabetes?
Yes. The Indian regulator CDSCO has approved tirzepatide for chronic weight management, not just type 2 diabetes.
The label criteria typically follow the standard global threshold: BMI 30 kg/m² or above (obesity), or BMI 27 kg/m² or above with at least one weight-related condition such as hypertension, dyslipidemia, sleep apnea, or prediabetes.
How long do I have to stay on the drug?
This is the question most people skip. GLP-1 drugs are chronic disease treatments, not short courses. Stopping the medication typically reverses appetite suppression within weeks.
Most patients regain a meaningful portion of the lost weight within a year unless they have built durable lifestyle changes during treatment. Talk to your doctor about a long-term plan before you start, not after.
Do health insurance plans in India cover Ozempic or Mounjaro?
Most retail health insurance plans in India do not currently cover GLP-1 drugs for weight management.
Some corporate wellness plans in metro cities have started experimenting with partial coverage for chronic-disease therapies, but this is rare and case-by-case. Check directly with your insurer.
| The bottom lineMounjaro is the more effective drug in head-to-head trials, both for diabetes control and for weight loss. It also got to the Indian market first, scaled fast, and is currently the most-prescribed option. Ozempic is a strong, well-established second choice, particularly for diabetes patients, and the post-March 2026 generic semaglutide wave is making access easier than it was a year ago.Neither drug is a shortcut. Both demand specialist supervision, careful screening for contraindications, slow dose escalation, and a long-term plan. The patients who get the best outcomes are the ones who treat the injection as one part of a structured medical programme, not as a standalone fix.If you are weighing the two, book a consultation with an endocrinologist or internal medicine specialist who has experience prescribing both. The right answer is the one that matches your clinical profile, not the one that is trending on your feed. |
